PTC THERAPEUTICS INC (PTCT)

US69366J2006 - Common Stock

33.095  -0.94 (-2.75%)

After market: 33.095 0 (0%)

News Image
5 days ago - PTC Therapeutics, Inc.

PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza™...

News Image
17 days ago - PTC Therapeutics, Inc.

PTC Therapeutics to Participate at Upcoming Investor Conferences

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: RBC...

News Image
18 days ago - Investor's Business Daily

PTC Therapeutics Stock Sees IBD RS Rating Climb To 72

PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72.

News Image
24 days ago - InvestorPlace

PTCT Stock Earnings: PTC Therapeutics Beats EPS, Beats Revenue for Q1 2024

PTCT stock results show that PTC Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

News Image
24 days ago - BusinessInsider

PTCT Stock Earnings: PTC Therapeutics Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips PTC Therapeutics (NASDAQ:PTCT) just reported results for the first quarter of 2...

News Image
24 days ago - PTC Therapeutics, Inc.

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

/PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2024....

News Image
a month ago - PTC Therapeutics, Inc.

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 19, 2024, the company approved non-statutory stock options to purchase an...

News Image
2 months ago - PTC Therapeutics, Inc.

PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin MAA to the European Medicines Agency. The MAA...

News Image
2 months ago - PTC Therapeutics, Inc.

PTC Therapeutics Provides Key Regulatory Updates

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the submission of a BLA to the U.S. FDA for Upstaza™ (eladocagene exuparvovec), a gene...

News Image
3 months ago - PTC Therapeutics, Inc.

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

/PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending...

News Image
3 months ago - Seeking Alpha

Notable earnings after Thursday's close

Major earnings expected after the bell on Thursday include:Zscaler (ZS)Hewlett Packard Enterprise Company (HPE)Dell Technologies (DELL)Autodesk (ADSK)Veeva...

News Image
3 months ago - PTC Therapeutics, Inc.

PTC Therapeutics to Participate at Upcoming Investor Conferences

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: TD Cowen...

News Image
3 months ago - PTC Therapeutics, Inc.

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Feb. 15, 2024, the company approved non-statutory stock options to purchase an...

News Image
3 months ago - PTC Therapeutics, Inc.

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and...

News Image
3 months ago - Market News Video

Notable Tuesday Option Activity: DIN, PTCT, TOL

News Image
3 months ago - Seeking Alpha

Biogen gets EU approval for Friedrich's ataxia drug (NASDAQ:BIIB)

Biogen (BIIB) said it has received EU approval for its drug Skyclarys for the treatment of Friedreich’s ataxia, or FA, in patients aged 16 years and older. Read more here.

News Image
3 months ago - The Motley Fool

1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?

Bad news for one player does not always equal good news for another.

News Image
4 months ago - Investor's Business Daily

PTC Therapeutics Flashes A Bearish Sign After European Officials Reject DMD Drug

European regulators will likely force PTC Therapeutics to pull its drug, Translarna, from the market.

News Image
4 months ago - Seeking Alpha

PTC Therapeutics down 10% as EMA issues Translarna negative opinion (NASDAQ:PTCT)

The European Medicines Agency's negative opinion on PTC Therapeutics' Translarna will result in the withdrawal of the treatment. Read more here.

News Image
4 months ago - PTC Therapeutics, Inc.

CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

News Image
4 months ago - PTC Therapeutics, Inc.

PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its commercial progress and R&D pipeline at the 42nd Annual J.P. Morgan...

News Image
5 months ago - PTC Therapeutics

PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 42nd Annual J.P. Morgan...

News Image
5 months ago - PTC Therapeutics, Inc.

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 10, 2023, the company approved non-statutory stock options to purchase an...

News Image
6 months ago - Seeking Alpha

PTC Therapeutics issues EU, US regulatory updates on Translarna (PTCT)

PTC Therapeutics (PTCT) has issued an update on its efforts to renew conditional approval for its drug Translarna in the EU and file for FDA approval in the US. Read more here.

News Image
6 months ago - PTC Therapeutics, Inc.

PTC Therapeutics Provides Updates on Translarna™ Regulatory Activities

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today an update on Translarna™ (ataluren) regulatory activities in Europe and the United States....

News Image
7 months ago - PTC Therapeutics, Inc.

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 1, 2023, the company approved non-statutory stock options to purchase an...